
News|Articles|November 19, 2012
Direct renin inhibitor adjunct not helpful in T2DM patients at high risk for CV, renal events
The direct renin inhibitor aliskiren, added to standard therapy with renin-angiotensin system blockade, in patients with type 2 diabetes who are at risk for cardiovascular and renal adverse events was not useful at lowering these events and may even be harmful, according to an online study published in the New England Journal of Medicine.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
What exactly is managed care today?
3
TrumpRx launches; some experts question its long-term value
4
PBM reform. It has finally happened
5























